China's HitGen to Discover Lead Molecules for LEO of Denmark

00:24 EDT 8 Aug 2017 | ChinaBio Today

HitGen Ltd. of Chengdu has begun a multi-target, multi-year collaboration with LEO Pharma A/S, a Danish dermatology company. Using its very large DNA-encoded library of novel leads, HitGen will discover novel small molecule leads for multiple targets specified by LEO. HitGen has established discovery partnerships with major global pharmas, including Janssen, Merck, Pfizer and Scripps Research Institute. Under the terms of the LEO agreement, HitGen will receive an upfront payment and be eligible for milestones. More details....

Share this with colleagues:

Original Article: China's HitGen to Discover Lead Molecules for LEO of Denmark


More From BioPortfolio on "China's HitGen to Discover Lead Molecules for LEO of Denmark"

Quick Search

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...